Generic Name and Formulations:
Hydrocortisone probutate 0.1%; crm.
Indications for PANDEL:
≥18yrs: apply thin film to affected area 1–2 times daily. Discontinue when control is achieved. Reassess if no improvement within 2 weeks.
<18yrs: not established.
Avoid near or around eyes, face, underarms, groin areas. Occlude only if necessary. Not for diaper dermatitis; do not use in diaper area. Evaluate for HPA axis suppression periodically (esp. in prolonged use, application to large surface area, use of occlusive dressings, impaired skin, or in children); discontinue or reduce dose or potency if occurs. Hepatic impairment. Diabetes. Discontinue if irritation develops. Avoid abrupt cessation. Pregnancy. Nursing mothers: use on the smallest area of skin for the shortest duration.
Burning, stinging, rash, redness, itching, paresthesia, contact dermatitis; HPA axis suppression (esp. in children), Cushing's syndrome, hyperglycemia, skin atrophy, secondary infections.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry